Cargando…

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review

PURPOSE: To evaluate 6-month treatment benefits with lifitegrast ophthalmic solution 5% in symptomatic dry eye patients. SETTING: Retrospective chart analysis. METHOD: A retrospective chart review was conducted in 168 patients (111 females and 57 males) who presented with symptoms of chronic dry eye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Atallah, Richard Teofilo, Castanos, Maria Virginia, Najac, Richard, Donnenfeld, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590901/ https://www.ncbi.nlm.nih.gov/pubmed/31354236 http://dx.doi.org/10.2147/OPTH.S191635

Ejemplares similares

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis
por: Li, Jing-Xing, et al.
Publicado: (2022)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Kinetics of Anti–SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection
por: Sakhi, Hamza, et al.
Publicado: (2021)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016
por: Nicastri, Emanuele, et al.
Publicado: (2016)

Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016
por: Barzon, Luisa, et al.
Publicado: (2016)

SIDRE: Symptomatic Improvement of Dry Eye Study
por: De Paz, Clarissa J, et al.
Publicado: (2017)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
por: Kissling, Esther, et al.
Publicado: (2019)

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
por: Barda, Noam, et al.
Publicado: (2022)

Ocular Distribution and Pharmacokinetics of Lifitegrast in Pigmented Rabbits and Mass Balance in Beagle Dogs
por: Chung, Jou-Ku, et al.
Publicado: (2018)

SARS‐CoV‐2 asymptomatic and symptomatic patients and risk for transfusion transmission
por: Corman, Victor M., et al.
Publicado: (2020)

Symptomatic asymmetry in the first six months of life: differential diagnosis
por: Nuysink, Jacqueline, et al.
Publicado: (2008)

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
por: Gulley, James L., et al.
Publicado: (2019)

Design, synthesis, and LFA-1/ICAM-1 antagonist activity evaluation of Lifitegrast analogues
por: Du, Guoxin, et al.
Publicado: (2022)

Lid wiper epitheliopathy in symptomatic and asymptomatic dry eye subjects
por: Kamath, Vandana, et al.
Publicado: (2023)

A triple combination of treatments on moderate COVID-19
por: Bao, ChunMiao, et al.
Publicado: (2021)

Late intraocular Lens dislocation following scleral depression: a case report
por: Castanos, Maria V., et al.
Publicado: (2020)

Revisiting the eye opening response of the Glasgow Coma Scale
por: Rabiu, Taopheeq Bamidele
Publicado: (2011)

High incidence of venous thrombosis in patients with moderate-to-severe COVID-19
por: Kerbikov, Oleg, et al.
Publicado: (2021)

Practical Synthesis of 5,7-Dichlorotetrahydroisoquinoline-6-carboxylic Acid—Key Intermediate of Lifitegrast (Xiidra)
por: Liu, Xu, et al.
Publicado: (2023)

PERSIST: Physician’s Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
por: Mah, Francis, et al.
Publicado: (2012)

Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
por: Suarez Castillo, Milena, et al.
Publicado: (2022)

Low SARS-CoV-2 Cq values in healthcare workers with symptomatic COVID-19 infections, regardless of symptom severity, The Netherlands, January to August 2022
por: van Rossum, Carsten, et al.
Publicado: (2023)

Lifitegrast add-on treatment for dupilumab-induced ocular surface disease (DIOSD): A novel case report
por: Zirwas, Matthew J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bm13j1ovgraoqcneb22m9rgpjl